uniQure (QURE), ClearPoint (CLPT): FDA Drops Sham-Surgery Control

Between March and August 2026, uniQure (QURE), ClearPoint Neuro (CLPT) and BioCardia (BCDA) each told investors on their quarterly earnings calls that the FDA no longer insists on a randomized sham-surgery control for rare-disease central nervous system gene therapy. With that part of the evidence bar lowered, the constraint on the products behind it has moved to a different layer: how the drug physically gets into the organ.

The approval path got shorter; the delivery path did not

A gene therapy is dosed once, packaging a therapeutic gene into a viral vector. Diseases inside the brain cannot be treated with an infusion, so a neurosurgeon uses image guidance to place a cannula at a specific intracranial target and injects the drug there. To show the effect was not placebo, the FDA used to require a sham-surgery control, in which some patients go through the same surgical procedure without receiving the drug. Rare diseases have few patients to begin with, surgeons are reluctant to put a patient through an operation for nothing, and families rarely accept it, so these trials have long been difficult to run [1].

That is the step the agency has now conceded. uniQure was told its three-year Phase I-II data can serve as the primary basis of its filing, with the control arm switched to patients on standard of care [2]. On its August call, ClearPoint's CEO said the FDA appears to have reversed its regulatory approach in some rare diseases, and named several other partners that received similar answers in the same window [3]. What remains after the shorter review is physical. ClearPoint sells the navigation system and single-use cannulas used for intracranial dosing, and is co-labeled with the drug developer, so once a therapy is approved the sponsor cannot swap that supplier out [3].

One revenue line, cut and then restored within five months

In March 2026, ClearPoint removed from its outlook all revenue tied to the commercial launch of two partner products, because the FDA was then requiring traditional Phase 3 trials in these rare diseases [4]. By August, the same CEO said those filings were back. The company revised 2026 revenue guidance to $48 million to $52 million, redirected spending away from sales expansion and toward clinical case support and capital equipment, and said it has only 12 to 15 months to get ready [3].

ClearPoint expects 10 to 15 trials using its technology to be enrolling patients over the next 18 months, and says 15 centers have each committed to one or two cases a week. A single uniQure procedure generates $15,000 to $25,000 of revenue for it, against $12,000 to $15,000 on average across its partners [3]. The cardiac side sits at an earlier stage. BioCardia says no catheter at all has been approved for transendocardial delivery, the route that injects into heart muscle from inside the chamber, and that the FDA has told it two clearance pathways exist [5]. The same regulatory turn already produces revenue in the brain, while in the heart the device category does not yet exist.

Pricing power sits with the delivery layer

Because the device is co-labeled with the therapy at approval, a sponsor that wants to change suppliers afterward has to go back through registration. ClearPoint says that relationship already converts into price: under commercial pricing agreements the same cannula carries different prices during bench testing, clinical trials and commercial launch, rising at each stage, and this has been easier to negotiate than a direct royalty on the drug [3]. For the sponsor, that cost sits inside the delivery cost per treated patient and scales with approvals. On the cardiac side, a de novo clearance — the pathway that creates a classification for an entirely new device type — would give later entrants a predicate to reference in a 510(k), turning delivery from something unavailable into something that can be bought [5].

The boundary is in the same disclosure. The FDA said it prefers the device to be approved simultaneously with the therapy, and only suggested a follow-on pre-submission that could support a standalone de novo [5]. The loosening is also case by case rather than a standing rule: PTC Therapeutics and Novartis are still running a Phase 3 trial of roughly 770 patients in the same indication where uniQure was released from sham control [6]. The checkable metric from here is ClearPoint's biologics and drug delivery revenue line, and how many of those 10 to 15 trials convert into commercial procedures in 2027 [3].

Companies exposed to this change

• MeiraGTx (MGTX): Its Parkinson's gene therapy is injected into the subthalamic nucleus in the brain, and its completed Phase 2 randomized 45 patients 1:1 against bilateral sham surgery — the company that actually paid the cost the FDA has now dropped. Whether its later design switches to a standard-of-care control has not been disclosed [7].
• Cryoport (CYRX): It runs the cold chain for cell and gene therapies and says it supports about 70% of the industry's clinical trials, 779 of them currently. Each additional approval gives one trial shipping lane the chance to become a per-patient commercial lane, though the company has not commented on this regulatory change specifically [8].
• NeuroOne (NMTC): The other public company building a route into the brain for biologics. Its robot-assisted StereoCED platform is planned to be ready for human studies by the end of September 2026, and it faces the same device-clearance gate as ClearPoint [9].

Sources

[1] Drillr · ClearPoint Neuro (CLPT) · 2026-05-13 · earnings call

[2] Drillr · uniQure (QURE) · 2026-07-29 · earnings call

"However, the critical point is that the FDA agreed that a randomized study using sham control is no longer required. The agency recommended instead that we run a randomized standard of care controlled study with total functional capacity at 36 months as the primary endpoint."

[3] Drillr · ClearPoint Neuro (CLPT) · 2026-08-03 · earnings call

[4] Drillr · ClearPoint Neuro (CLPT) · 2026-03-17 · earnings call

[5] Drillr · BioCardia (BCDA) · 2026-08-12 · earnings call

[6] Drillr · PTC Therapeutics (PTCT) · 2026-07-30 · earnings call

[7] Drillr · MeiraGTx (MGTX) · 2026-03-30 · FY2025 annual report (Form 10-K)

[8] Drillr · Cryoport (CYRX) · 2026-08-06 · earnings call

[9] Drillr · NeuroOne Medical Technologies (NMTC) · 2026-08-13 · earnings call

This is only here to help you spot industry changes and companies you may have missed - it is not a stock recommendation.